GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Gossamer Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.43−0.34 (-3.88%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$166.77 (−95.19%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Gossamer Bio, Inc. grew revenue 32.4% to $53.29M over the twelve months to Jun 30, 2026. Free cash flow was -$162.63M.
Revenue
$53.29M
+32.4% vs. a year earlier
Operating income
-$166.09M
TTM Q2 2026
Free cash flow
-$162.63M
TTM Q2 2026
EPS, diluted
-$0.69
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.77B
- P/E ratio
- –
- Price to sales
- 52.01
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -5.87%
Fundamentals
- Revenue
- $53.29M
- Net income
- -$125.22M
- EPS, diluted
- -$0.69
- Free cash flow
- -$162.63M
- Book value per share
- -$0.29
- Diluted shares
- 329M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$53.29M+32.4% YoY
Operating income
-$166.09M
Net income
-$125.22M
EPS, diluted
-$0.69
Free cash flow
-$162.63M
Reported periodTrailing twelve months